Advertisement

U.S. markets open in 9 hours 4 minutes

S&P Futures
5,887.00
-5.50(-0.09%)
Dow Futures
43,041.00
-128.00(-0.30%)
Nasdaq Futures
20,511.75
-30.25(-0.15%)
Russell 2000 Futures
2,243.20
-3.00(-0.13%)
Crude Oil
72.24
+0.15(+0.21%)
Gold
2,761.80
+2.00(+0.07%)

Moberg Pharma AB (publ) (MBGPF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed Price. Currency in USD

1.0100

-0.0400

(-3.81%)

At close: 10:44AM EDT

Loading interactive chart...

Premium
MT Newswires
Cipher Pharmaceuticals Down 16% as Partner Moberg Pharma AB Provides Lower Than Expected Study Results
Cipher Pharmaceuticals Down 16% as Partner Moberg Pharma AB Provides Lower Than Expected Study Results
PR Newswire
Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients
Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus. The number of patients who have achieved clinical cure in this blinded subset of patients is lower than the company's expectations, which necessitates that Moberg Pharma inform the market about this fact.